Delivery Order SPE2DB24D1205-SPE2DB25FCZWP
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on August 18, 2025, by the Defense Logistics Agency (DLA) for the supply of Tamsulosin HCl 0.4 mg capsules in a quantity of 1,000 units. The contract was competitively awarded with no set-aside designation at a firm fixed price of $3,592.77, with an ultimate completion date of August 19, 2025. The place of performance is located in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for 1,000 capsules of Tamsulosin HCL 0.4 mg with a ceiling value of $3,750.17. This is a firm fixed price delivery order with an ultimate completion date of August 22, 2025, and was awarded on August 21, 2025, through open competition with no set-aside designation. The order will be fulfilled at the company's Corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of 1,000 units of Tamsulosin HCL 0.4 mg capsules, with a contract ceiling value of $1,727.65. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by August 8, 2025. The award represents a routine pharmaceutical supply transaction supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg at a firm fixed price of $1,857.60, with an ultimate completion date of August 25, 2025. This non-set-aside contract was competitively awarded and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,189.17 firm fixed-price delivery order is for the supply of 1,000 units of the prescription drug Tamsulosin HCl 0.4 mg capsules. The contract has an ultimate completion date of April 4, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which...
- The Defense Logistics Agency awarded a delivery order valued at $2,609.16 to AmerisourceBergen Drug Corp for 1,000 capsules of Tamsulosin HCL 0.4 mg, with delivery expected by July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value pharmaceutical procurement supporting military healthcare supply needs. The place of performance is listed as AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $1,691.07 to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of 4,565,111,422 units of Tamsulosin HCL 0.4 mg capsules. This order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a wide range of pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg, with a contract value of $2,520.50. The award, issued on August 8, 2025, is a firm fixed price delivery order with an ultimate completion date of August 11, 2025. This is a non-set-aside, competitively awarded contract, and performance will be executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a...
- The Defense Logistics Agency awarded a delivery order valued at $1,613.70 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of 1,000 capsules of Tamsulosin HCL 0.4 mg. This contract employs a firm fixed price delivery order structure with no set-aside designation, indicating competitive award. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 18, 2025. This delivery order is issued...
- The U.S. Defense Logistics Agency (DLA) awarded a $1,902.08 firm-fixed-price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 4,564,310,884 capsules of Tamsulosin HCL 0.4 mg. This order is part of Amerisourcebergen's Indefinite Delivery Contract (IDC) valued up to $999,999,999.00 with the DLA Troop Support Medical, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and...
- SPE2DB24D1205Indefinite Delivery Contract
- SPE2DB24D1205-SPE2DB25FCZWPDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 25, 2025, for the supply of Tamsulosin HCl 0.4 mg capsules in a quantity of 1,000 units, with a ceiling value of $3,848.04. The contract utilizes firm fixed price pricing and is scheduled for completion by August 26, 2025, with performance at the company's Conshohocken, Pennsylvania facility. This delivery order represents a non-set-aside competitive award and operates as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the DLA Medical Supply Chain. The company supplies an extensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including brand-name and generic medications, vaccines, and specialized medical commodities across multiple therapeutic domains. The parent IDC vehicle enables flexible procurement of pharmaceutical support for customers including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with the DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts with multiple regional award recipients.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.8k | 8/25/25 |